According to the World Health Organization (WHO), as of April 20, about 6% of the world's population has been diagnosed with the new crown.

With the continuous mutation of the virus and the continuous recurrence of epidemics in many countries, how to minimize the risk of the epidemic and finally overcome the epidemic has become an international concern.

　　At the Boao Forum for Asia Annual Conference 2022, many participants pointed out that scientific anti-epidemic has always been the core content of anti-epidemic, and increasing the vaccination rate of the country and narrowing the global immunization gap is always the top priority to minimize the risk of the epidemic Heavy.

One-third of the world's population is not vaccinated

　　The existence of the immunization gap between different countries is a shortcoming of global epidemic prevention and control, and provides more possibilities for virus mutation.

　　According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), more than 13 billion doses of the vaccine have been produced globally since the outbreak began, of which 11 billion have been injected.

According to the latest research report by British research company Airfinity, due to the oversupply of global vaccine production, the global sales of COVID-19 vaccines this year are expected to be lowered from $80.8 billion to $64.1 billion.

　　However, the vaccine production target achieved beyond expectations has not completely changed the current situation of unfair distribution of vaccines.

　　Former British Prime Minister Gordon Brown provided a set of data at the forum. Currently, there are still one-third of people in the world who have not received the first dose of the new crown vaccine, and these groups include 20% of the world's most vulnerable groups.

　　Taking Africa as an example, 84% of the African population has not received any injections of the new crown vaccine, and only about 5% of the population has received the second dose of the new crown vaccine.

　　"In Africa, there are still many people who are hesitant, which requires the government to continuously advance the national vaccination plan and inform citizens of the necessity and importance of vaccination." Mohammad Hassani, Assistant to the Minister of Public Health of Egypt, said at the forum.

　　In addition to this subjective factor, Mohammad Hassani also pointed out that in the region, insufficient self-sufficiency in vaccine production, short-term funding for vaccine procurement and imperfect medical equipment have also hindered local epidemic prevention and control.

　　"We hope to promote the stability of the local supply chain of new crown pharmaceutical products and the improvement of medical infrastructure conditions by strengthening international cooperation." Mohammad Hassani appealed.

　　Mohammad Hassani said that, as one of the first countries to receive vaccines from China National Pharmaceutical Group and Kexing Group, Egypt has achieved a national vaccination rate of over 70% through two years of efforts; The cooperation has also made Egypt the first country in Africa that can provide vaccine production.

At present, the vaccines produced by Egypt can not only satisfy self-sufficiency, but also support other countries. For example, Egypt has provided Pakistan with 500,000 doses of vaccine support.

　　Miao Xiang, President of Shenzhen Kangtai Biology, further stated at the forum that, from the perspective of vaccine production capacity reserve, there are still bottlenecks to produce large quantities of vaccines in a short period of time and inject them into vulnerable groups and people in less developed countries, and it is necessary for a global Countries will further strengthen cooperation and make joint plans.

　　"We look forward to establishing a vaccine development and production coordination mechanism at the global level to promote fairness and accessibility of vaccines' global distribution," said Miao Xiang.

　　In order to allow vaccines to reach more low-income regions around the world, international organizations and regional cooperation organizations shoulder important responsibilities.

　　As a representative of the WHO's partner organization, Ted Chaiban, the global chief coordinator of the 2019-nCoV vaccine delivery partnership, said at the forum that the delivery of the new crown vaccine between countries with different regions, different political systems, and different medical systems Coordination by international organizations is needed to improve the efficiency of vaccine scheduling.

　　On the other hand, Ted Chaiban said that low-income countries often do not have enough funds to support vaccine distribution networks, and this shortcoming also requires coordination and assistance from international organizations.

　　"It is gratifying that, under the effective promotion of various parties, the number of countries with a global vaccination rate of less than 10% has been reduced from 34 in January to 19 now." Ted Chaiban revealed.

Vaccination booster can strengthen immune barrier

　　As the global new crown epidemic enters its third year, the virus mutation is still continuing, and the completion of the whole course of vaccination is no longer enough to build an immune barrier, and the booster vaccination has become the most effective way to effectively reduce the severity and mortality of the new crown in the world at this stage. , one of the most feasible ways.

　　"Through more than two years of practice, we have seen that booster vaccination may be the best immunization program at this stage." Zheng Zhongwei, head of the working group of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said at the forum.

　　According to Zheng Zhongwei, at the beginning of the outbreak, the World Health Organization's hope for vaccine research and development was to complete the research and development process as quickly as possible and expand its penetration rate.

Therefore, according to this goal, the simpler the immunization procedure, the better.

However, with the evolution of the epidemic, more than two years of practice have proved that two injections are not enough to achieve the best protective effect, and the third injection is imperative.

　　Taking Hong Kong as an example, Zheng Zhongwei said that two types of vaccines are mainly used in Hong Kong, one is inactivated vaccine and the other is mRNA vaccine. , After the third injection, the vaccine's protective effect on severe cases quickly reached 98%.

　　Zhang Wenhong, director of the National Center for Infectious Diseases Medicine and director of the Department of Infectious Diseases of Huashan Hospital Affiliated to Fudan University, further emphasized the importance of strengthening the protection of the elderly and immunocompromised groups at the forum.

　　Zhang Wenhong said that reducing the fatality rate of the elderly and vulnerable groups such as those with underlying diseases is a very important indicator that the world can finally get rid of the epidemic.

In this regard, it is necessary to strengthen the vaccination of these vulnerable groups, especially the booster vaccination.

　　So, is there a risk to vaccinating against the new crown for the elderly with weak immune systems and underlying diseases?

　　In response, Zheng Zhongwei said that, on the one hand, from China's data, it can be seen that the overall safety of the new coronavirus vaccination, that is, the incidence of adverse reaction times, is slightly lower than that of the vaccines that were routinely used in the past; on the other hand , Because the elderly are often accompanied by underlying diseases, if the new coronavirus vaccine is not vaccinated, the risk of infection will be higher.

　　According to CBC statistics in the United States, compared with people aged 18 to 29, people aged 65 to 74 have a 5-fold increased risk of hospitalization and a 65-fold increased risk of death after being diagnosed with the new crown; 75- to 84-year-olds have an 8-fold increased risk of hospitalization. , the risk of death will increase by 140 times; the risk of hospitalization for people over 85 years old will increase by 10 times, and the risk of death will increase by 340 times.

　　"In foreign countries, the highest age of Chinese vaccine recipients is over 106 years old. In China, the highest age of Chinese new crown vaccine recipients has reached 111 years old. Among them, a large part of them suffer from underlying diseases. According to the above data, We believe that as long as it is not in the acute attack stage of the underlying disease, the elderly can be vaccinated." Zheng Zhongwei said.